Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The firm says that regarding the two amyloid beta-directed therapies on the market, it is becoming clear that competitive dynamics are not at all amounting to a zero-sum game. That’s the good news. That said, Piper continues to see a commercial footprint for the category that is quite limited in the context of the sheer size of the Alzheimer’s disease space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments
- Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment?
- Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment
- Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
- Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study